Bioceltix S.A.

Warsaw Stock Exchange BCX.WA

Bioceltix S.A. EPS (Diluted) for the year ending December 31, 2023: USD -0.89

Bioceltix S.A. EPS (Diluted) is USD -0.89 for the year ending December 31, 2023, a -45.23% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Bioceltix S.A. EPS (Diluted) for the year ending December 31, 2022 was USD -0.61, a -77.22% change year over year.
  • Bioceltix S.A. EPS (Diluted) for the year ending December 31, 2021 was USD -0.34, a -35.19% change year over year.
  • Bioceltix S.A. EPS (Diluted) for the year ending December 31, 2020 was USD -0.25, a -97.26% change year over year.
  • Bioceltix S.A. EPS (Diluted) for the year ending December 31, 2019 was USD -0.13, a -101.25% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
Warsaw Stock Exchange: BCX.WA

Bioceltix S.A.

CEO Mr. Lukasz Bzdzion
IPO Date Nov. 8, 2021
Location Poland
Headquarters Building III
Employees 28
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

StockViz Staff

January 15, 2025

Any question? Send us an email